COMPLEXES OF D-TYPE CYCLINS WITH CDKS DURING MAIZE GERMINATION

Silvia K Godínez-Palma<sup>1</sup>, Elpidio García<sup>1</sup>, María de La Paz Sánchez<sup>2</sup>, Fernando Rosas<sup>1</sup>, Jorge M Vázquez-Ramos<sup>1</sup>

CycD11																	
	CycD1;1	CycD2;1	CycD2;2a	CycD2;2b	CycD2;3	CycD3;1a	CycD3;1b	CycD4;1a	CycD4;1b	CycD4;2	CycD5;1	CycD5;2a	CycD5;2b	CycD5;3a	CycD5;3b	CycD6;1	CycD7;1
CycD4;	2 12.30%	28.40%	30.60%	29.50%	17.00%	21.00%	19.40%	30.70%	32.20%	ID	8.80%	12.20%	13.10%	17.70%	13.30%	7.80%	6.60%
CycD5;3	a 10.90%	14.40%	17.40%	17.40%	13.00%	7.00%	5.50%	13.60%	16.90%	17.70%	12.10%	10.70%	10.60%	ID	64.60%	6.20%	5.00%
CycD5;3	b 8.00%	13.00%	15.60%	15.60%	13.80%	5.00%	4.60%	12.60%	14.00%	13.30%	3.20%	7.80%	6.10%	64.60%	ID	6.50%	4.20%

CdkA;1	MEQYEKVEKIGEGTYGVVYKALDKATNETIALK	33
CdkA;2	MEQYEKVEKIGEGTYGVVYKALDKATNETIALK	33
CdkA;3	MDQYEKVEKIGEGTYGVVYKGKDRHTNETIALK	33
CdkB1;1	MPLPIDGRRERAVCVRGAGAGAMEINIVIKYEKLEKVGEGTYGKVYKAQDKATGQLVALK	60
CdkB1;2	MATIONKPTPTAPSTTTGGGLRAMDLYDKLEKVGEGTYGKVYKAREKATGRIVALK	55
CdkB3	-MATIQHQAKPAVAAAPSTTTGGGQRAMDLYEKLEKVGEGTYGKVYRAREKATGRIVALK	59
	1 **	
CdkA;1 CdkA;2	KIRLEQEDEGVPSTAIREISLLKEMNHG-NIVRLHDVVHSEKRIYLVFEYLDLDL KIRLEOEDEGVPSTAIREISLLKEMNHG-NIVRLHDVVHSEKRIYLVFEYLDLDL	87 87
CdkA;2	KIRLEQEDEGVPSTAIREISLLKEMNHG-NIVRLHDVVHSEKRIYLVFEYLDLDL	87
CdkA;3	KIRLEQEDEGVPSTAIRE SLLKEMQHR-NIVRLQEVVHNDKCIYLVFEYLDLDL	87
CdkB1;1	KTRLEMDEEGIPPTALRE SLLNLLSHSIYIVRLLAVEQAAKN-GKPVLYLVFEFLDTDL	119
CdkB1;2	KTRLPEDDEGVPPTALREVSLLRMLSQDPHVVRLLDLKQGVNKEGQTILYLVFEYMDTDL	115
CdkB3	KTRLPEDDEGVPPTAMREVSLLRMLSQDPHVVRLLDLKQGVNKEGQTILYLVFEYMDTDL	119
	2	

CdkA;1	${\tt LADFGLARAFGIPVRTFThevvtlwyrapeillgarqystpvdvwsvgcifaemvnqkpl$	203	
CdkA;2	${\tt LadfglarafgipvrtfThevvtlwyrapeillgarqystpvdvwsvgcifaemvnqkpl}$	203	
CdkA;3	${\tt LadfglarafgipvrtfThevvtlwyrapeillgarhystpvdvwsvgcifaemvnqkal}$	202	
CdkB1;1	${\tt iadlglgraftvpmksyTheivtlwyrapevllgathystgvdmwsvgcifaemarrqal}$	239	
CdkB1;2	${\tt iadlglsraitvpvkkyTheiltlwyrapevllgathystpvdiwsvgcifaelvtnqpl$	233	
CdkB3	${\tt iadlglsraitvpvkkyTheiltlwyrapeillgathystpvdiwsvgcifaelvtnqpl$	237	

53.7% identity between CDKAs and CDKB1;1

FIGURE S1

B)



**FIGURE S2** 



FIGURE S3



**FIGURE S4** 



FIGURE S5



FIGURE S6

## Supplementary data.

**Supplementary Figure S1**. Comparison of maize D-type Cyclins sequences. A) Alignment of carboxyl ends of the 17 maize D-type Cyclins and percentage identity of Cyclins D4;2 and D5;3 compared to all maize cyclins. B) Comparison of maize CDK sequences. Motif 1, sequence used for production of anti-CDKB1;1 antibodies; Motif 2, canonical PSTAIRE-Cyclin binding sequence (in Cdc2-type kinases like CDKA), PPTAL(M)RE in CDKB. (\*) Represents phosphorylatable T14, Y15 and T160 residues, conserved in all CDKs.

Supplementary Figure S2. Validation of antibodies against D-type cyclins and CDKs. Panels A and B, lanes 1 and 3, protein extracts from non-imbibed maize axes and recombinant proteins incubated with the corresponding antibody, lanes 2, recombinant proteins incubated only with pre-immune serum. Panel A, antibodies against GST-Cyclin D4;2 and GST-CyclinD5;3; Panel B, antibodies against His-CDKA and GST-CDKB1;1. Panels C and D, Specificity of antibodies. Panel C, lanes 1, protein extracts from non-imbibed maize axes, lanes 2, GST-CycD4;2, lanes 3, GST-CycD5;3; C1), Western blot using anti-CycD4;2 antibody, C2) Western blot using anti-CycD5;3 antibody. Panel D, lanes 1, protein extracts from non-imbibed maize axes, lanes 2, His-CDKA, lanes 3, GST-CDKB1;1; D1), Western blot using anti-CDKA antibody, D2), western blot using anti-CDKB1;1 antibody. Panels E and F, recognition of CDKs. Panel E1, increasing concentrations of protein extracts (50 to 300 µg) from non-imbibed maize axes and recognition of CDKs using the anti-CDKA antibody. Notice the recognition of a 37kDa band (CDKB1;1) at 250 µg protein; panel E2, same as above but recognition with anti-CDKB1;1 antibody (only CDKB1;1 is recognized). Membranes stained with Ponceau Red are shown as loading control. Panel F. immunoprecipitation with anti-CDKA antibody. F1, immunoprecipitation of samples with increasing concentrations of protein extracts (100 to 300 µg) from non-imbibed maize axes, using anti-CDKA antibody and recognition by anti-CDKA antibodies of

34 kDa (CDKA) and 37 kDa (CDKB1;1) bands, the latter is observed only in the 300  $\mu$ g sample. F2, western blot using anti-CDKB1;1 antibody of proteins immunoprecipitated by anti-CDKA antibodies in samples of increasing concentrations of protein extracts from non-imbibed maize axes (150, 200 y 300  $\mu$ g). Only the 37 kDa band is detected at 300  $\mu$ g. C(+), proteins extracts from non-imbibed axes (50  $\mu$ g); C(-), immunoprecipitation with anti-CDKA antibody, no protein extract added.

**Supplementary Figure S3**. Stability of Cyclins D during germination. Maize embryo axes were imbibed for 9 h in the presence of cycloheximide (introduced by means of vacuum) and then the presence of Cyclins D was followed by western blot. Lanes 1, 4 and 7, protein extracts from 9 h imbibed maize axes in the absence of cycloheximide. Lanes 2, 5 and 8, protein extracts from 9 h imbibed maize axes, with a 5 min vacuum treatment at the beginning of the imbibition time. Lane 3, 6 and 9, protein extracts from 9 h imbibed maize axes, treated with vacuum and cycloheximide. Loading control as in Fig. 2.

**Supplementary Figure S4**. Validation of the sequential immunoprecipitation technique (according to Fig. 5). Lane C) Immunoprecipitation (0, 6, 12, 18 and 24h germination) and western blot of each one of D-type Cyclins after heat treatment (65°C, 3h) and removal of D-type Cyclins-CDKs complexes. Lane D) Immunoprecipitation of CDKB1;1 from the supernanat containing D-type Cyclins-CDKs complexes from step B and identification of CDKB1;1 and D-type Cyclins by western blot. Lane E) Immunoprecipitation of CDKA from the supernatant obtained in step D and identification of CDKA and D-type Cyclins by western blot. Positive control, identification of the target protein in protein extracts from non-germinated seed axes. Negative control, high molecular weight IgGs.

**Supplementary Figure 5.** Alkaline phosphatase and CDK activity. Lane 1 (C+), kinase activity in cyclin-CDK complexes pulled down by CKS protein; lane 2, kinase activity in anti-CycD2;2 immunoprecipitate; lane 3, dephosphorylation of

substrate used in lane 2 (RBR protein) by alkaline phosphatase; lane 4, inhibition of alkaline phosphatase activity by 40 min pre-incubation with inhibitor and kinase activity in anti-CycD2;2 immunoprecipitate; lane 5 C(-), anti-CycD2;2 immunoprecipitate with no protein extract added; lane 6, pre-incubation of alkaline phosphatase with inhibitor (40 min), then substrate and <sup>32</sup>P were added and then incubation with anti-CycD2;2 immunoprecipitate; lane 7, pre-incubation of alkaline phosphatase with <sup>32</sup>P and inhibitor, then the substrate and finally anti-CycD2;2 immunoprecipitate; lane 8, preincubation of alkaline phosphatase and <sup>32</sup>P (40 min), then the kinase assay.

**Supplementary Figure 6**. Kinase activity after a high temperature treatment. Panel A, lane 1 (C+), kinase activity in cyclin-CDK complexes bound to CKS protein; lane 2, kinase activity in CycD2;2-CDKA complexes (heat-treated); lane 3, kinase activity in CycD2;2-CDKB1;1 complexes (heat-treated); lane 4, kinase activity in anti-CDKA immunoprecipitates (no heat treatment); lane 5, kinase activity in anti-CDKB1;1 immunoprecipitates (no heat treatment); lane 6 (C-), kinase activity in anti-CycD2;2 immunoprecipitates with no protein extract added. Panel B, lane 1 (C+), kinase activity in cyclin-CDK complexes bound to CKS protein, lane 2, kinase activity in anti-CycD2;2 immunoprecipitates; lane 3, kinase activity in anti-CDKA immunoprecipitates; lane 4, kinase activity in anti-CDKB1;1 immunoprecipitates; lane 4, kinase activity in anti-CDKB1;1 immunoprecipitates; lane 5, kinase activity in cyclin-CDK complexes pulled down by a p13Suc1 resin; lane 6, kinase activity in cyclin-CDK complexes pulled down by a p13Suc1 resin treated at 65°C for 3h; lane 7, kinase activity in anti-CycD2;2 immunoprecipitates with no protein extract added.